Amyloidosis: A review of recent diagnostic and therapeutic developments

British Journal of Haematology

Volumn 99, Issue 2, 1997, Pages 245-256

  Gillmore, Julian D ^a   Hawkins, Philip N ^a   Pepys, Mark B ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Amyloid; Amyloidosis; SAP; Scintigraphy

Indexed keywords

4' IODOESORUBICIN; ALPHA2B INTERFERON; AMYLOID; AMYLOID PRECURSOR PROTEIN; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTHROPATHY; BLOOD DYSCRASIA; BONE ATROPHY; CARDIOTOXICITY; EDEMA; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEPSIS;

EID: 0030682237     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.303194.x     Document Type: Review

References (77)

1. Ahlmen, M., Ahlmen, J., Svalander, C. & Bucht, H. (1987) Cytotoxic drug treatment of reactive amyloidsis in rheumatoid arthritis with special reference to renal insufficieny. Clinical Rheumatology, 6, 27-38.
2. Axelrad, M.A., Kisilevsky, R., Willmer, J., Chen, S.J. & Skinner, M. (1982) Further characterisation of amyloid-enhancing factor. Laboratory Investigation, 47, 139-146.
3. Baltz, M.L., Caspi, D., Evans, D.J., Rowe, I.F., Hind, C.R.K. & Pepys, M.B. (1986) Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clinical and Experimental Immunology, 66, 691-700.
4. Bardin, T. (1994) Low-dose prednisone in dialysis-related amyloid arthropathy. Revue du Rhumatisme [English Edition], 61, (Suppl.), 97S-100S.
5. Benson, M.D., Liepnieks, J., Uemichi, T., Wheller, G. & Correa, R. (1995) Hereditary renal amyloidosis associated with a mutant librinogen α-chain. Nature Genetics, 3, 252-255.
6. Benson, M.D. & Uemichi, T. (1996) Transthyretin amyloidosis. Amyloid: The International Journal of Experimental and Clinical Investigations, 3, 44-56.
7. Berglund, K., Keller, C. & Thysell, H. (1987) Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Annals of the Rheumatic Diseases, 46, 757-762.
8. Booth, D., Sunde, M., Bellotti, V., Robinson, C., Hutchinson, L., Fraser, P., Hawkins, P., Dobson, C., Radford, S., Blake, C. & Pepys, M. (1997) Instability, unfolding, and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 385, 787-793.
9. Camoriano, J., Greipp, P., Bayer, G. & Bowie, E. (1987) Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. New England Journal of Medicine, 316, 1133-1135.
10. Comenzo, R.L., Sarnacki, D., Finn, K., Falk, R., Sanchorawala, V., Akpek, G., Farhat, M. & Voshurgh, E. (1996) AL amyloidosis responds to high-dose melphalan and blood stem cells. (Abstract). Blood, 88, (Suppl. 1), 686a.
11. Costa, P.P., Figueira, A.S. & Bravo, F.R. (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proceedings of the National Academy of Sciences of the United States of America, 75, 4499-4503.
12. David, J. (1991) Amyloidosis in juvenile chronic arthritis. Clinical and Experimental Rheumatology, 9, 73-78.
13. Delgado, A.W. & Mosqueda, A. (1989) A highly sensitive method for diagnosis of secondary amyloidosis by labial salivary gland biopsy. Journal of Oral Pathology and Medicine, 18, 310-314.
14. Duchen, L.W. (1992) Current status review: cerebral amyloid. International Journal of Experimental Pathology, 73, 535-550.
15. Falck, H.M., Törnroth, T., Skrifvars, B. & Wegelius, O. (1979) Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Medica Scandinavica, 205, 651-656.
16. Gagnon, R.F., Bourgouin, P., Lough, J., Somerville, P. & Kaye, M. (1986) Carpal tunnel syndrome with beta 2-microglobulin-containing amyloid and continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 8, A6.
17. 2-microglobulin. Biochemical and Biophysical Research Communications, 129, 701-706.
18. Gertz, M. & Kyle, R. (1993) Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. American Journal of Hematology, 44, 125-128.
19. Gertz, M.A. & Kyle, R.A. (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine, 70, 246-256.
20. Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1991) Response rates and survival in primary systemic amyloidosis. Blood, 77, 257-262.
21. Gertz, M.A., Kyle, R.A. & O'Fallon, W.M. (1992) Dialysis support of patients with primary systemic amyloidosis: a study of 211 patients. Archives of Internal Medicine, 152, 2245-2250.
22. Glenner, G.G. (1980a) Amyloid deposits and amyloidosis: the β-fibrilloses. I. New England Journal of Medicine, 302, 1283-1292.
23. Glenner, G.G. (1980b) Amyloid deposits and amyloidosis: the β-fibrilloses. II. New England Journal of Medicine, 302, 1333-1343.
24. Goldfinger, W.E. (1972) Colchicine for familial Mediterranean fever. New England Journal of Medicine, 287, 1302.
25. 2-microglobulin in tissues causes amyloidosis in patients on chronic hemodialysis. Proceedings of the National Academy of Sciences of the United States of America, 83, 7908-7912.
26. Greipp, P.R., Kyle, R.A. & Bowie, E.J., (1979) Factor X deficiency in primary amyloidosis: resolution after splenectomy. New England Journal of Medicine, 301, 1050-1051.
27. Griepp, P.R., Kyle, R.A. & Bowie, E.J.W. (1981) Factor X deficiency in amyloidosis: a critical review. American Journal of Hematology, 11, 443-450.
28. Hall, R. & Hawkins, P.N. (1994) Cardiac transplantation for AL amyloidosis. British Medical Journal 309, 1135-1137.
29. Hartmann, A., Holdaas, H., Fauchald, P., Nordal, K.P., Berg, K.J. & Talseth, T. (1992) Fifteen years' experience with renal transplantation in systemic amyloidosis. Transplant international, 5, 15-18.
30. Hawkins, P.N., Hall, M., Hall, R., Penny, L., Henderson, A., Yacoub, M., Mitchell, A. & Pepys, M.B. (1994a) Regression of AL amyloidoisis and prolonged survival following cardiac transplantation and chemotherapy. Amyloid and Amyloidosis 1993 (ed. by R. Kisilevsky, M. D. Benson, B. Frangione, J. Gauldie, T. J. Muckle and I. D. Young), pp. 657-659. Parthenon Publishing, Pearl River, New York.
31. 123I-labelled serum amyloid P component. New England Journal of Medicine, 323, 508-513.
32. 123I-labeled serum amyloid P component. Journal of Experimental Medicine, 167, 903-913.
33. Hawkins, P.N., Myers, M.J., Lavender, J.P. & Pepys, M.B. (1988b) Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet, i, 1413-1418.
34. Hawkins, P.N., Persey, M.R., Lovat, L.B., Madhoo, S., McCarthy, M., Heaton, N., Williams, R. & Pepys, M.B. (1996) UK experience of liver transplantation in FAR. Neuromuscular Disorders, 6, S77.
35. Hawkins, P.N., Peters, A.M., Vigushin, D.M., Richardson, S., Seymour, A., Holmgren, G., Steen, L., Woo, P., Hall, A. & Pepys, M.B. (1993a) SAP scintigraphy and turnover studies demonstrate regression of amyloidosis. Nuclear Medicine Communications, 14, 259-260.
36. Hawkins, P.N., Richardson, S., Vigushin, D.M., David, J., Kelsey, C.R., Gray, R.E.S., Hall, M.A., Woo, P., Lavender, J.P. & Pepys, M.B. (1993b) Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis and Rheumatism, 36, 842-851.
37. Hawkins, P.N., Vigushin, D.M., Richardson, S., Seymour, A., Holmgren, G., Steen, L., Woo, P., Hall, A., Peters, A.M. & Pepys, M.B. (1994b) Natural history and regression of amyloidosis. Amyloid and Amyloidosis 1993 (ed. by R. Kisilevsky, M. D. Benson, B. Frangione, J. Gauldie, T. J. Muckle and I. D. Young), pp. 638-641. Parthenon Publishing, Pearl River, New York.
38. Hawkins, P.N., Vigushin, D.M., Richardson, S., Seymour, A. & Pepys, M.B. (1994c) Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy. Amyloid and Amyloidosis 1993 (ed. by R. Kisilevsky, M. D. Benson, B. Frangione, J. Gauldie, T. J. Muckle and I.D. Young), pp. 209-211. Parthenon Publishing, Pearl River, New York.
39. Holmgren, G., Ericzon, B.-G., Groth, C.-G., Steen, L., Suhr, O., Andersen, O., Wallin, B.G., Seymour, A., Richardson, S., Hawkins, P.N. & Pepys, M.B. (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet, 341, 1113-1116.
40. 30). Clinical Genetics, 40, 242-246.
41. Hosenpud, J.D., DeMarco, T., Frazier, O.H., Griffith, B.P., Uretsky, B.F., Mentis, A.H., O'Connell, J.B., Olivari, M.-T. & Valantine, H.A. (1991) Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation, 84, 338-343.
42. Husby, G. (1992) Nomenclature and classification of amyloid and amyloidoses. Journal of Internal Medicine, 212, 511-512.
43. Jadoul, M., Malghem, J., Pirson, Y., Maldague, B. & van Ypersele de Strihou, C. (1989) Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clinical Nephrology, 32, 194-197.
44. Koch, K.M. (1992) Dialysis-related amyloidosis. (Clinical conference). Kidney International, 41, 1416-1429.
45. Kyle, R.A. & Bayrd, E.D. (1975) Amyloidosis: a review of 236 cases. Medicine, 54, 271-299.
46. Kyle, R., Gertz, M., Greipp, P., Witzig, T., Lust, J., Lacy, M. & Therneau, T. (1997) A trial of three regimes for primary amyloidosis: colchicine alone, melphalan and prednisolone, and melphalan, prednisolone and colchicine. New England Journal of Medicine, 336, 1202-1207.
47. Kyle, R.A. & Greipp, P.R. (1978) Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood, 52, 818-827.
48. Kyle, R.A. & Greipp, P.R. (1983) Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clinic Proceedings, 58, 665-683.
49. Kyle, R.A., Greipp, P.R., Garton, J.P. & Gertz, M.A. (1985) Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. American Journal of Medicine, 79, 708-716.
50. Kyle, R.A., Greipp, P.R. & O'Fallon, M. (1986) Primary systemic amyloidosis: multivariate anlysis for prognostic factors in 168 cases. Blood, 68, 220-224.
51. Livneh, A., Zemer, D., Langevitz, P., Shemer, J., Sohar, E. & Pras, M. (1993) Colchicine in the treatment of AA and AL amyloidosis. Seminars in Arthritis and Rheumatism, 23, 206-214.
52. Lorenzo, A., Razzaboni, B., Weir, G.C. & Yankner, B.A. (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature, 368, 756-760.
53. Martinez-Vea, A., Garcia, C., Carreras, M., Revert, L & Oliver, J.A. (1990) End-stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis. American Journal of Nephrology, 10, 283-289.
54. Maury, C.P.J. (1991) Gelsolin-related amyloidosis: identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin. Journal of Clinical Investigation, 87, 1195-1199.
55. Merlini, G., Ascari, E., Amboldi, N., Bellotti, V., Arbustini, E., Perfetti, V., Ferrari, M., Zorzoli, I., Marinone, M., Garini, P., Diegoli, M., Trizio, D. & Ballinari, D. (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of fibrillogenesis. Proceedings of the National Academy of Sciences of the United States of America, 92, 2959-2963.
56. Moroni, G., Banfi, G., Montoli, A., Bucci, A., Bertani, T., Ravelli, M., Pozzi, C., Leonelli, M., Lupo, A., Volpi, A., Pasquali, S. & Salvadeo, A. (1992) Chronic dialysis in patients with systemic amyloidosis: the experience in Northern Italy. Clinical Nephrology, 38, 81-85.
57. Nelson, S., Sharpestone, P. & Kingswood, J. (1993) Does dialysis-related amyloidosis resolve after transplantation? Nephrology, Dialysis, Transplantation, 8, 369-370.
58. Nelson, S.R., Lyon, M., Gallagher, J.T., Johnson, E.A. & Pepys, M.B. (1991) Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochemical Journal, 275, 67-73.
59. Nichols, W.C., Gregg, R.E., Brewer, H.B.J. & Benson, M.D. (1990) A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics, 8, 318-323.
60. Pasternack, A., Ahonen, J. & Kuhlback, B. (1986) Renal transplantation in 45 patients with amyloidosis. Transplantation, 42, 598-601.
61. Pepys, M.B. (1995) Amyloidosis. Oxford Textbook of Medicine, Vol. 2, 3rd edn (ed. by D. J. Weatherall, J. G. G. Ledingham and D. A. Warrell), pp. 1512-1524. Oxford University Press.
62. Pepys, M.B., Hawkins, P.N., Booth, D.R., Vigushin, D.M., Tennent, G.A., Soutar, A.K., Totty, N., Nguyen, O., Blake, C.C.F., Terry, C.J., Feest, T.G., Zalin, A.M. & Hsuan, J.J. (1993) Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature, 362, 553-557.
63. Pepys, M.B., Rademacher, T.W., Amatayakul-Chantler, S., Williams, P., Noble, G.E., Hutchinson, W.L., Hawkins, P.N., Nelson, S.R., Gallimore, J.R., Herbert, J., Hutton, T. & Dwek, R.A. (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proceedings of the National Academy of Sciences of the United States of America, 91, 5602-5606.
64. Persey, M.R., Lovat, L.B., Apperley, J.F., Madhoo, S., Pepys, M.B. & Hawkins, P.N. (1996) Intensive chemotherapy for AL amyloidosis. British Journal of Rheumatology, 35, (Suppl. 1), 12.
65. Puchtler, H., Sweat, F. & Levine, M. (1962) On the binding of Congo red by amyloid. Journal of Histochemistry and Cytochemistry, 10, 355-564.
66. Ravid, M., Shapira, J. & Kedar, I. (1977) Prolonged colchicine treatment in four patients with amyloidosis. Annals of Internal Medicine, 87, 568-570.
67. Saraiva, M.J.M., Birken, S., Costa, P.P. & Goodman, D.S. (1984) Amyloid fibril protein in familial amyloid polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). Journal of Clinical Investigation, 74, 104-119.
68. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D. & Younkin, S. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine, 2, 864-870.
69. Schnitzer, T.J. & Ansell, B.M. (1977) Amyloidosis in juvenile chronic polyarthritis. Arthritis and Rheumatism, 20, 245-252.
70. Soutar, A.K., Hawkins, P.N., Vigushin, D.M., Tennent, G.A., Booth, S.E., Hutton, T., Nguyen, O., Totty, N.F., Feest, T.G., Hsuan, J.J. & Pepys, M.B. (1992) Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 89, 7389-7393.
71. Tan, S.-Y., Irish, A., Winearls, C.G., Brown, E.A., Gower, P.E., Clutterbuck, E.J., Madhoo, S., Lavender, J.P., Pepys, M.B. & Hawkins, P.N. (1996) Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney International, 50, 282-289.
72. Tan, S.-Y., Pepys, M.B. & Hawkins, P.N. (1995) Treatment of amyloidosis. American Journal of Kidney Diseases, 26, 267-285.
73. Vigushin, D.M., Pepys, M.B. & Hawkins, P.N. (1994a) Rapid regression of AA amyloidosis following surgery for Castleman's disease. Amyloid and Amyloidosis 1993 (ed. by R. Kisilevsky, M. D. Benson, B. Frangione, J. Gauldie, T. J. Muckle and I. D. Young), pp. 48-50. Parthenon Publishing, Pearl River, New York.
74. Vigushin, D.M., Vulliamy, T., Kaeba, J.S., Hawkins, P.N., Luzzatto, L. & Pepys, M.B. (1994b) Immunoglobulin gene rearrangement analysis in AL amyloidosis. Amyloid and Amyloidosis 1993 (ed. by R. Kisilevsky, M. D. Benson, B. Frangione, J. Gauldie, T. J. Muckle and I. D. Young), pp. 287-289. Parthenon Publishing, Pearl River, New York.
75. Westermark, P. & Stenkvist, B. (1975) A new method for the diagnosis of systemic amyloidosis. Archives of Internal Medicine, 132, 522-523.
76. Wilkins, J., Gallimore, J.R., Tennent, G.A., Hawkins, P.N., Limburg, P.C., van Rijswijk, M.H., Moore, E.G. & Pepys, M.B. (1994) Rapid automated enzyme immunoassay of serum amyloid A. Clinical Chemistry 40, 1284-1290.
77. Wisniewski, K., Wisniswski, H. & Wen, G. (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals of Neurology, 17, 278-282.